SCHEMBL268098

SCHEMBL268098

Cc1ccc(/C=N/NC(=O)c2c(C)csc2NC(=O)c2cccc(C(S)c3nc[nH]n3)c2)cc1C

nearest known ligand 0.37

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CTDSP1 Q9GZU7 2/20 0.37
POLB P06746 7/20 0.35
HPGD P15428 1/20 0.35
BLM P54132 1/20 0.35
CASP3 P42574 1/20 0.35
SENP8 Q96LD8 1/20 0.35
SENP7 Q9BQF6 1/20 0.35
SENP6 Q9GZR1 1/20 0.35
RAB9A P51151 7/20 0.35
NPC1 O15118 6/20 0.35
LMNA P02545 3/20 0.35
MAPT P10636 3/20 0.35
SMN1; SMN2 Q16637 2/20 0.35
NFKB1 P19838 1/20 0.35
NFKB2 Q00653 1/20 0.35
RELA Q04206 1/20 0.35
KMT2A Q03164 5/20 0.34
MEN1 O00255 4/20 0.34
ALDH1A1 P00352 1/20 0.34
NR1I2 O75469 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL270113 0.93 NPC1 (0.42) RAB9ANPC1LMNAMAPTSMN1; SMN2
SCHEMBL268493 0.92 RAB9A (0.44) CTDSP1POLBHPGDRAB9ANPC1
SCHEMBL269451 0.91 GUSB (0.41) CTDSP1POLBHPGDRAB9ANPC1
SCHEMBL267434 0.91 MAPT (0.42) POLBHPGDRAB9ANPC1MAPT
SCHEMBL269798 0.89 CTDSP1 (0.37) CTDSP1POLBHPGDBLMCASP3
SCHEMBL268192 0.88 SLC34A2 (0.44) POLBRAB9ANPC1LMNAMAPT
SCHEMBL266125 0.84 HPGD (0.39) POLBHPGDCASP3SENP8SENP7
SCHEMBL266893 0.84 KMT2A (0.38) CTDSP1POLBHPGDCASP3SENP7
SCHEMBL268099 0.81 MAPT (0.39) CTDSP1POLBHPGDBLMRAB9A
SCHEMBL273903 0.81 MAPT (0.39) CTDSP1POLBHPGDBLMRAB9A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20120115851-A1 COMPOUND INHIBITING IN VIVO PHOSPHORUS TRANSPORT AND MEDICINE CONTAINING THE SAME KYOWA HAKKO KIRIN CO., LTD. (JP) 2012-05-10 US disclosed
US-8134015-B2 Compound inhibiting in vivo phosphorous transport and medicine containing the same KYOWA HAKKO KIRIN CO., LTD. (JP) 2012-03-13 US disclosed
US-20060217426-A1 Compound inhibiting in vivo phosphorous transport and medicine containing the same KIRIN BEER KABUSHIKI KAISHA (JP) 2006-09-28 US disclosed
EP-1614676-A1 COMPOUND INHIBITING IN VIVO PHOSPHORUS TRANSPORT AND MEDICINE CONTAINING THE SAME KIRIN BEER KABUSHIKI KAISHA (JP) 2006-01-11 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060217426-A1 Compound inhibiting in vivo phosphorous transport and medicine containing the same SLC10A6, SLC7A1, SLC10A1 CTDSP1 2003/4885POLB 3843/4885HPGD 2509/4885
US-20120115851-A1 COMPOUND INHIBITING IN VIVO PHOSPHORUS TRANSPORT AND MEDICINE CONTAINING THE SAME SLC34A1, SLC34A2, SLC20A2 CTDSP1 1785/4885POLB 3761/4885HPGD 2407/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.